004310 — Hyundai Pharmaceutical Co Share Price
Last trade - 00:00- KR₩96bn
- KR₩124bn
- KR₩181bn
- 55
- 41
- 14
- 26
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.12 | ||
| Price to Tang. Book | 1.2 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.51 | ||
| EV to EBITDA | 13.33 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 6.85% | ||
| Return on Equity | 5.58% | ||
| Operating Margin | 3.3% | ||
Financial Summary
| Year End 30th Nov | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 134,649.74 | 132,965.51 | 139,802.75 | 162,690.05 | 180,762.66 | n/a | n/a | 6.69% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | -1.92 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
HYUNDAI PHARMACEUTICAL CO.,LTD is a Korea-based company principally engaged in the manufacture and distribution of pharmaceuticals and beverages. The Company mainly provides two categories of products: pharmaceuticals, including ophthalmological tablets, clopidogrel bisulfate, mirtazapine tablets and others, which are applied in the treatment of depressive disorder, hypertension, hemostatics and others, as well as healthcare food products, including vitamin products, calcium supplements and others. It also provides dietary various beverages and medical equipment. The Company mainly distributes its products within domestic market. In addition, the Company also involves in the leasing business.
Directors
- Han Gu Lee CHM (65)
- Chang Hyeon Yoon CCE (66)
- Yeong Hak Kim VPR (57)
- Sang Jun Lee VPR (43)
- Yi Sun Hwang VPR (51)
- Jong Gyu Lee VPR (53)
- Seong Won Choi OTH (41)
- Seok Bong Lee OTH (55)
- Jong Deok Park OTH (41)
- Cheon Su Ham NID (66)
- Yong Wun Kim NID (67)
- Last Annual
- November 30th, 2023
- Last Interim
- February 29th, 2024
- Incorporated
- July 16th, 1965
- Public Since
- June 28th, 1978
- No. of Shareholders
- 23,232
- No. of Employees
- 387
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KSE
- Shares in Issue
- 26,372,380
- Address
- 55, CHEONAN, 31213
- Web
- http://www.hyundaipharm.co.kr/
- Phone
- +82 415705114
- Auditors
- Sahmhwa Accounting Corp.
Upcoming Events for 004310
Similar to 004310
Aprogen Biologics
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm Co
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
CKD Bio
Korea Exchange - KSE
FAQ
As of Today at 21:13 UTC, shares in Hyundai Pharmaceutical Co are trading at KR₩3,565. This share price information is delayed by 15 minutes.
Shares in Hyundai Pharmaceutical Co last closed at KR₩3,565 and the price had moved by -16.61% over the past 365 days. In terms of relative price strength the Hyundai Pharmaceutical Co share price has underperformed the FTSE Developed Asia Pacific Index by -20.2% over the past year.
There is no consensus recommendation for this security.
The Hyundai Pharmaceutical Co dividend yield is 0.98% based on the trailing twelve month period.
Last year, Hyundai Pharmaceutical Co paid a total dividend of KR₩35, and it currently has a trailing dividend yield of 0.98%. We do not have any data on when Hyundai Pharmaceutical Co is to next pay dividends.
We do not have data on when Hyundai Pharmaceutical Co is to next pay dividends. The historic dividend yield on Hyundai Pharmaceutical Co shares is currently 0.98%.
To buy shares in Hyundai Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩3,565, shares in Hyundai Pharmaceutical Co had a market capitalisation of KR₩94bn.
Here are the trading details for Hyundai Pharmaceutical Co:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 004310
Based on an overall assessment of its quality, value and momentum Hyundai Pharmaceutical Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hyundai Pharmaceutical Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -7.92%.
As of the last closing price of KR₩3,565, shares in Hyundai Pharmaceutical Co were trading -7.78% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Hyundai Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩3,565.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Hyundai Pharmaceutical Co's management team is headed by:
- Han Gu Lee - CHM
- Chang Hyeon Yoon - CCE
- Yeong Hak Kim - VPR
- Sang Jun Lee - VPR
- Yi Sun Hwang - VPR
- Jong Gyu Lee - VPR
- Seong Won Choi - OTH
- Seok Bong Lee - OTH
- Jong Deok Park - OTH
- Cheon Su Ham - NID
- Yong Wun Kim - NID